Provided by Tiger Trade Technology Pte. Ltd.

Viking Therapeutics

30.55
+0.60002.00%
Volume:997.07K
Turnover:30.04M
Market Cap:3.56B
PE:-6.55
High:30.62
Open:30.02
Low:29.80
Close:29.95
52wk High:43.15
52wk Low:22.96
Shares:116.65M
Float Shares:110.00M
Volume Ratio:1.05
T/O Rate:0.91%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.6676
EPS(LYR):-3.1920
ROE:-88.85%
ROA:-51.86%
PB:8.73
PE(LYR):-9.57

Loading ...

Lilly: Foundayo Has Captured Over 30% Of New Patient Share In The U.S. Oral Weight-Loss Drug Market

Bellwether Stocks Movement
·
Sep 15

AstraZeneca's Breast Cancer Drug Etcamah Hits A Phase 3 Setback, Clouding Billions In Potential Sales

Options & Short Sell
·
Sep 14

GE HealthCare Plans $1 Billion Sofie Deal To Tap Fast-Growing Radiopharmaceuticals Market

Options & Short Sell
·
Sep 14

Viking Therapeutics to Present at Morgan Stanley Global Healthcare Conference Fireside Chat

Reuters
·
Sep 03

Der Aktionaer editor speculates on timing of Viking Therapeutics data

TIPRANKS
·
Aug 25

Viking Therapeutics (VKTX) Stock Still Looks Pricey With Pipeline Hopes Priced In

Simply Wall St.
·
Aug 20

Viking Therapeutics Director Dorothy Elizabeth Kelly-Gemmell Files Initial Beneficial Ownership Statement

Reuters
·
Aug 08

Viking Therapeutics Posts Corporate Presentation Outlining Obesity Drug Pipeline Led by Vk2735 Phase 3 Program

Reuters
·
Aug 06

Viking Therapeutics' VK2735 Drives Substantial Optionality, Oppenheimer Says

MT Newswires Live
·
Aug 04

Oppenheimer says VK2735’s options create compelling reason to own Viking

TIPRANKS
·
Aug 03

Analysts Offer Insights on Healthcare Companies: Viking Therapeutics (VKTX), AbbVie (ABBV) and Cencora (COR)

TIPRANKS
·
Aug 01

Tenax Therapeutics Q2 Net Loss Widens on Higher R&D Costs

Reuters
·
Jul 31

Viking's Obesity Treatments Advance as New Data, Trials Loom, Oppenheimer Says

MT Newswires Live
·
Jul 31

Viking Therapeutics is Maintained at Buy by Canaccord Genuity

Dow Jones
·
Jul 31

Viking Therapeutics (VKTX) Receives a Buy from Jefferies

TIPRANKS
·
Jul 30

Truist Financial Sticks to Their Buy Rating for Viking Therapeutics (VKTX)

TIPRANKS
·
Jul 30

Madrigal Pharmaceuticals Q2 Revenue Rises 71% on Rezdiffra Demand

Reuters
·
Jul 30

Viking Therapeutics Inc Files for Mixed Shelf; Size not Disclosed - SEC Filing

THOMSON REUTERS
·
Jul 30

Viking Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Jul 30

Viking Therapeutics Reports Q2 Milder-than-expected Net Loss as Obesity Trials Advance

Reuters
·
Jul 30